Literature DB >> 35273671

Acute complications in children with sickle cell disease: Prevention and management.

Carolyn E Beck1, Evelyne D Trottier1, Melanie Kirby-Allen1, Yves Pastore1.   

Abstract

Sickle cell disease (SCD) is a chronic, multi-system disease that requires comprehensive care. The sickling of red blood cells leads to hemolysis and vascular occlusion. Complications include hemolytic anemia, pain syndromes, and organ damage. Patterns of immigration and an increase in newborn screening mean that paediatric health care providers across Canada, in small and large centres alike, need to be knowledgeable about SCD. This statement focuses on principles of prevention, advocacy, and the rapid treatment of common acute complications. Guidance includes the current status of newborn screening, recommendations for immunizations and antibiotic prophylaxis, and an introduction to hydroxyurea, a medication that reduces both morbidity and mortality in children with SCD. Case vignettes demonstrate principles of care for common acute complications of SCD: vaso-occlusive episodes (VOE), acute chest syndrome (ACS), fever, splenic sequestration, aplastic crises, and stroke. Finally, principles of blood transfusion are highlighted, along with indications for both straight and exchange blood transfusions. © Canadian Paediatric Society 2022. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Hemoglobinopathy; Hemolytic anemia; Hydroxyurea; Newborn screening

Year:  2022        PMID: 35273671      PMCID: PMC8900682          DOI: 10.1093/pch/pxab096

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  15 in total

1.  Newborn screening for sickle cell disease: effect on mortality.

Authors:  E Vichinsky; D Hurst; A Earles; K Kleman; B Lubin
Journal:  Pediatrics       Date:  1988-06       Impact factor: 7.124

2.  Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Authors:  Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson
Journal:  Lancet       Date:  2011-05-14       Impact factor: 79.321

3.  The Changing Epidemiology of Pediatric Hemoglobinopathy Patients in Northern Alberta, Canada.

Authors:  Catherine Corriveau-Bourque; Aisha A K Bruce
Journal:  J Pediatr Hematol Oncol       Date:  2015-11       Impact factor: 1.289

4.  The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Authors:  Martin H Steinberg; William F McCarthy; Oswaldo Castro; Samir K Ballas; F Danny Armstrong; Wally Smith; Kenneth Ataga; Paul Swerdlow; Abdullah Kutlar; Laura DeCastro; Myron A Waclawiw
Journal:  Am J Hematol       Date:  2010-06       Impact factor: 10.047

5.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

6.  A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease.

Authors:  J A Wilimas; P M Flynn; S Harris; S W Day; R Smith; P J Chesney; J H Rodman; J M Eguiguren; D L Fairclough; W C Wang
Journal:  N Engl J Med       Date:  1993-08-12       Impact factor: 91.245

7.  Impact of hydroxyurea on clinical events in the BABY HUG trial.

Authors:  Courtney D Thornburg; Beatrice A Files; Zhaoyu Luo; Scott T Miller; Ram Kalpatthi; Rathi Iyer; Phillip Seaman; Jeffrey Lebensburger; Ofelia Alvarez; Bruce Thompson; Russell E Ware; Winfred C Wang
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

8.  Ceftriaxone-induced immune hemolytic anemia.

Authors:  Gal Neuman; Sabrina Boodhan; Ilana Wurman; Gideon Koren; Ari Bitnun; Melanie Kirby-Allen; Shinya Ito
Journal:  Ann Pharmacother       Date:  2014-08-27       Impact factor: 3.154

9.  Evaluation of a clinical protocol using intranasal fentanyl for treatment of vaso-occlusive crisis in sickle cell patients in the emergency department.

Authors:  Hugo Paquin; Evelyne D Trottier; Yves Pastore; Nancy Robitaille; Marie-Joelle Dore Bergeron; Benoit Bailey
Journal:  Paediatr Child Health       Date:  2019-03-07       Impact factor: 2.253

10.  American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.

Authors:  M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad
Journal:  Blood Adv       Date:  2020-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.